Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Atai Life Sciences this morning reported early data from its Phase 1b trial testing an oral form of the psychedelic DMT for treatment-resistant depression. The drug, VLS-01, is meant to induce a ...

Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and T NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI ...

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinical development of short ...

NEW YORK and BERLIN – atai Life Sciences (NASDAQ: ATAI), a biopharmaceutical company focused on mental health disorders, announced positive preliminary results from a Phase 1b trial of VLS-01 ...

Atai Life Science announced promising preliminary results for its DMT-based depression therapy. The company notes that effectiveness, safety and mild side effects can be expected in the potential ...

1 Day ATAI 1.53% DJIA 0.14% Russell 2K 1.32% Health Care/Life Sciences 1.81% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View Atai Life Sciences N.V. (ATAI) current and estimated P/E ratio data provided by Seeking Alpha.